Filing Details
- Accession Number:
- 0001140361-15-044058
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-12-09 20:24:14
- Reporting Period:
- 2015-12-07
- Filing Date:
- 2015-12-09
- Accepted Time:
- 2015-12-09 20:24:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1416792 | Relypsa Inc | RLYP | Pharmaceutical Preparations (2834) | 260893742 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1477384 | A John Orwin | C/O Relypsa, Inc. 100 Cardinal Way Redwood City CA 94063 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-12-07 | 10,000 | $7.40 | 69,375 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-12-07 | 6,821 | $27.85 | 62,554 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-07 | 7,379 | $28.52 | 55,175 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-07 | 800 | $29.67 | 54,375 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2015-12-07 | 10,000 | $0.00 | 10,000 | $7.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 727,877 | 2023-07-23 | No | 4 | M | Direct |
Footnotes
- Includes 54,375 restricted stock units.
- The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.28 to $28.2790, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.2835 to $29.1385, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Billionaire Hedge Funds
